You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

brentuximab vedotin

( bren-tuk-see-mab ve-doe-tin )
New Drug Funding Program
  • Brentuximab Vedotin – Relapsed or Refractory Hodgkin Lymphoma
  • Brentuximab Vedotin – Systemic Anaplastic Large Cell Lymphoma
  • Brentuximab Vedotin – Consolidation Post-Autologous Stem Cell Transplant (ASCT) for Hodgkin Lymphoma
Other Name(s): Adcetris®
Appearance: Clear to slightly opalescent, colorless solution mixed into larger bags of fluids for injection

You might also be interested in